Accès ouvert
2026
article
OpenAlex
Guglielmo Vetere, Emerik Österlund, Mahmoud Yousef, Songwit Payapwattanawong et autres
Background Immune checkpoint inhibitors (ICIs) have limited efficacy in proficient mismatch repair/microsatellite stable (pMMR/MSS) metastatic colorectal cancer (mCRC). However, selected patients with specific metastatic patterns may derive benefit. Methods Patients with chemorefractory pMMR/MSS mCRC treated with ICI-based regimens were retrospectively identified. A …
us, it, sa
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Guglielmo Vetere, Emerik Österlund, Mahmoud M.G. Yousef, Songwit Payapwattanawong et autres
202 Background: Immune checkpoint inhibitors (ICIs) have limited efficacy in microsatellite stable (MSS) metastatic colorectal cancer (mCRC), though selected patients may derive durable benefit. We evaluated survival outcomes of MSS mCRC patients treated with ICI-based regimens versus standard of care (SOC), with …
us, it, sa
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Guglielmo Vetere, Sebastian Correa Cautino, Mahmoud M.G. Yousef, Songwit Payapwattanawong et autres
203 Background: The mode of presentation of CRC has implications for early detection and prognosis. Our aim was to characterize presentation and symptoms at CRC diagnosis by primary location, RAS / BRAF , and mismatch repair (MMR) status at scale. Methods: A …
us, pr, it, sa
(code pays fourni par la source)
2026
conference-abstract
OpenAlex
Alisha Heather Bent, Christine Megerdichian Parseghian, Van K. Morris, Victoria Serpas Higbie et autres
TPS270 Background: Multiple studies demonstrate that circulating tumor DNA (ctDNA) captures radiographically occult micrometastases and predicts colorectal cancer (CRC) recurrence with a positive predictive value approaching 100%. The average lead-time of ctDNA positivity to radiographic recurrence is 6-9 months, which provides a …
us
(code pays fourni par la source)
Accès ouvert
2026
conference-abstract
OpenAlex
Emerik Österlund, Guglielmo Vetere, Songwit Payapwattanawong, Kristin D Alfaro et autres
140 Background: MRD is a state where circulating tumor DNA (ctDNA) is detected without visible radiologic disease after curative intent procedures. As this is associated with a high risk of recurrence, several clinical trials are ongoing for CRC in this setting with …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Christopher G. Smith, Clodagh Murray, Kathryn E. Aziz, Tim Forshew et autres
Introduction: Circulating tumor DNA (ctDNA) represents a promising tool for detection of minimal residual disease (MRD) and treatment monitoring in patients with cancer. Assays designed to detect ctDNA must demonstrate reproducibility across technical updates. This study evaluated concordance between two versions of …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Emerik Österlund, Giulia Maddalena, Andrew Jared Pellatt, Madhulika Eluri et autres
3591 Background: ctDNA is a promising tool for early cancer detection and monitoring of minimal residual disease (MRD). The relationship between vesicle trafficking of ctDNA-laden exosomes and shedding of detectable ctDNA in patients is poorly understood and was therefore explored in a …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Mahmoud M.G. Yousef, Sali Albarouki, Ahmed Elhariri, Guglielmo Vetere et autres
4179 Background: It is well documented that Pancreatic ductal adenocarcinoma (PDAC) metastasize to the liver had worse outcome than to the lung, but the molecular basis was less clear. We employ a large Real-World Evidence dataset to evaluate clinical and molecular features …
us
(code pays fourni par la source)
2025
article
OpenAlex
Alisha Heather Bent, Christine Megerdichian Parseghian, Van Karlyle Morris, Bryan K. Kee et autres
e15534 Background: The successful utilization of circulating tumor DNA (ctDNA) for the identification of micrometastatic disease has fueled the exploration of therapeutic options in colorectal cancer (CRC). While ongoing studies are evaluating the efficacy of novel medical therapies in CRC patients with …
us
(code pays fourni par la source)
2025
conference-abstract
OpenAlex
Mahmoud Yousef, Abdelrahman M.G. Yousef, Kristin D Alfaro, Giulia Maddalena et autres
816 Background: More than 44,000 patients are seen at MD Anderson Cancer Center annually. However, using the diverse, mostly unstructured, data from these patient encounters has been challenging and required manual chart reviews. In 2018, MD Anderson and Palantir Technologies (Denver, CO) …
us
(code pays fourni par la source)
Accès ouvert
2025
article
OpenAlex
Jumanah Yousef Alshenaifi, Guglielmo Vetere, Giulia Maddalena, Mahmoud Yousef et autres
Introduction Colorectal cancer (CRC) incidence and mortality before 50 have been rising alarmingly in the recent decades.Methods Using a cohort of 10,000 patients, this study investigates the clinical, mutational, and co-mutational features of CRC in early-onset (EOCRC, < 50 years) compared to …
us
(code pays fourni par la source)
Accès ouvert
2024
article
OpenAlex
Chemtai Mungo, Rakiya Saidu, Rebecca Luckett, Kristin D Alfaro et autres
A number of challenges hinder artificial intelligence (AI) models from effective clinical translation. Foremost among these challenges is the lack of generalizability, which is defined as the ability of a model to perform well on datasets that have different characteristics from the …
us
(code pays fourni par la source)